TEVA
Teva- Pharmaceutical Industries Ltd ADR
$36.36-0.71%
Setup
No setup
Buy Zone
$36.69-$38.52
Sector
Drug Manufacturers - Specialty & Generic
Industry
Drug Manufacturers - Specialty & Generic
35
Recommendation
Avoid
Avoid
Too many CANSLIM criteria failing.
TEVA chart
Loading chart…
ADX
Weak or Absent11.7Long Term
Range →Intermediate Term
Range →Short Term
Down ↓Overall Quality35
RS Rating
89
relative strength
Fundamentals
21
Weak fund-Q
Volume Demand
68
+34% vs avg
Technical Setup
63
5/8 checks
Industry/Theme
91
Drug Manufacturers - Specialty & Generic
Trade Plan
Avoid
Entry
$36.69
Entry Zone
$36.69-$38.52
Stop / Risk
$33.75
RS Rating
89
Volume confirmed
No
Targets
$44.03 / $45.86
Breakout · IBD Setup
6 ✓ 2 ✗
Entry $36.69–$38.52Stop $33.75Target $44.03 / $45.86
Market regimeUptrend
Quality35
RS Rating89
Above 50-MA+5.04%
Above 200-MA+11.62%
VolumeWeak
In Buy ZoneYes
Not extendedOK
Invalidation · Close below stop
How this came together
35
MarketUptrend
SetupNo setup
ConfidenceExperimental · not backtested
Fund-Q21 · Weak
StatusAvoid
Stock Data
52-Week Range18 – 38
Price % Chg YTD16.5%
Price % Chg 4wk4.45%
50-Day Avg Vol5.5 Mil
P/E Ratio61.1
Market Cap$42B
SectorHealthcare
IndustryDrug Manufacturers - Specialty & Generic
Company Fundamentals
EPS % Chg (Qtr)-302.7%
Sales % Chg (Qtr)-1.79%
EPS Growth 5y—
Sales Growth 5y0.8%
Annual ROE9.6%
Gross Margin52.53%
Operating Margin18.79%
Net Margin4.01%
Debt / Equity2.18
Setup levels
Current price
$36.36
Pivot
$36.69
Distance to buy
-5.2%
52-week range
18.21-38.37
Trigger evidence
No active trigger evidence available.
Financial health checks
0/5
Return on equity above 15%
ROE 9.6%
Net margin above 10%
Net margin 4.01%
EPS growing quarter on quarter
EPS q/q -302.7%
Sales growing quarter on quarter
Sales q/q -1.79%
Debt to equity below 1.0
D/E 2.18
Key metrics
Finviz snapshot · value vs. sector median (≥5 peers)
Annual ROE9.6%
vs sector -12.5%
Net margin4.01%
vs sector -13.0%
Gross margin52.53%
vs sector -14.1%
EPS growth q/q-302.7%
vs sector -310.7%
Sales growth q/q-1.79%
vs sector -20.3%
Debt / equity2.18
vs sector +1.54
Business quality
21
GradeWeak
EPS rating4
P/E61.1
Market cap$42B
IndustryDrug Manufacturers - Specialty & Generic
Technical checks
Über 50-MA
Pass
Über 200-MA
Pass
RS-Linie auf neuem Hoch
Fail
Volumen bestätigt
Fail
In Kaufzone
Pass
Nicht überextended
Pass
Über 21-EMA
Fail
Volumen gesund
Pass
IBD / source mentions
No recent IBD mention found for this ticker.
Signal history
Added to list
2026-09-01
Trigger date
—
Days on list
6
Data sources: internal CANSLIM engine · Finviz snapshot · TradingView chart. Not investment advice.